Singapore markets close in 1 hour 2 minutes
  • Straits Times Index

    3,045.55
    -25.68 (-0.84%)
     
  • Nikkei

    30,500.05
    +176.75 (+0.58%)
     
  • Hang Seng

    24,072.94
    -847.82 (-3.40%)
     
  • FTSE 100

    6,877.81
    -85.83 (-1.23%)
     
  • BTC-USD

    44,738.87
    -3,361.67 (-6.99%)
     
  • CMC Crypto 200

    1,115.42
    -110.11 (-8.98%)
     
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow

    34,584.88
    -166.42 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.93 (-0.91%)
     
  • Gold

    1,753.90
    +2.50 (+0.14%)
     
  • Crude Oil

    71.16
    -0.81 (-1.13%)
     
  • 10-Yr Bond

    1.3700
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,532.76
    -15.75 (-1.02%)
     
  • Jakarta Composite Index

    6,069.20
    -64.04 (-1.04%)
     
  • PSE Index

    6,857.90
    -54.95 (-0.79%)
     

Talis Biomedical to Announce Second Quarter 2021 Financial Results on August 10, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MENLO PARK, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the second quarter after market close on Tuesday, August 10, 2021. Talis will host a conference call, beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss financial and operational results.

Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 5966606. A live and archived webcast of the event can be accessed via the News & Events page of the investor section of Talis Biomedical’s website at www.talis.bio.

About Talis Biomedical
Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the point-of-care, beginning with COVID-19. The company is developing Talis One, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis is headquartered in Menlo Park, California. For more information, please visit talis.bio.

Contact
Media & Investors
Emily Faucette
ir@talisbio.com
415-595-9407


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting